Hyderabad, India headquartered Apollo Hospitals and Siemens Healthineers launched a research collaboration to advance AI-enabled diagnostic and imaging solutions particularly for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as NAFLD. This initiative aims to enhance early detection, risk assessment, and monitoring through quantitative ultrasound and AI-driven clinical tools.
MASLD affects between 9% and 32% of India’s population, with higher prevalence among individuals with obesity, diabetes, or other metabolic disorders. National data shows that almost 20% of Indian adults are overweight or obese, and 3–8% have abnormal blood sugar levels. The disease is also associated with elevated cardiovascular risk, making early intervention critical.
Dr. Sangita Reddy of Apollo Hospitals emphasized the importance of integrating AI with clinical expertise to overcome diagnostic challenges and improve patient outcomes. Incidentally, when I spoke at the India Conference at Harvard University, Sangita had a front row seat. Later she and I had a 30 minute private discussion about how Apollo’s
Hariharan Subramanian of Siemens Healthcare emphasized the role of advanced technologies in promoting early diagnosis and lifestyle-based prevention.
The partnership was formalized through a Master Research Agreement in March 2025, with an addendum signed in July 2025 in Hyderabad. The collaboration will focus on developing non-invasive, precision tools for liver care across clinical settings.
Last updated: December 26th, 2025
